A pharmacological inhibitor of the TGF-β1 pathway (Figure 3), galunisertib, has been tested in patients with neuroblastoma [174] and HCC [175], and an increased NK cell activity against tumor cells was observed [174]. This evidence concerns the gene TGFB1 and neoplasm.